Optimization of HER2-based and cell-based ELISA for detection of trastuzumab biosimilar

References

• 1.
  Thongsuksai P, Chongsuvivatwong V, Sriplung H. Delay in breast cancer care: a study in Thai women. Med Care 2000; 38: 108-114.
• 2.
  Taslimi Y, Zahedifard F, Habibzadeh S, Taheri T, Abbaspour H, Sadeghipour A, et al. Antitumor effect of IP-10 by using two different approaches: live delivery system and gene therapy. J Breast Cancer 2016; 19: 34-44.
• 3.
  Semnani V, Farhidzadeh E, Mirmohammadkhani M, Ghahremanfard F. Investigation of blood levels of vitamin D in women with breast cancer and its correlation with prognostic markers. Koomesh 2017; 735-741. (Persian).
• 4.
  Parise CA, Bauer KR, Brown MM, Caggiano V. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004. Breast J 2009; 15: 593-602.
• 5.
  Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2012; 9: 16-32.
• 6.
  Ahmadi A, Mohagheghi MA, Fazeli MS, Nahavandian B, Bashardoost N, Jarahi AM, Gharipoor M. HESA-A: new treatment for breast cancer and choroidal metastasis. Med Sci Monit 2005; 11: CR300-CR303.
• 7.
  Murphy CG, Modi S. HER2 breast cancer therapies: a review. Biologics 2009; 3: 289-301.
• 8.
  Kauraniemi P, Kallioniemi A. Activation of multiple cancer-associated genes at the ERBB2 amplicon in breast cancer. Endocr Relat Cancer 2006; 13: 39-49.
• 9.
  Foroumadi S, Rajabi bazl M, Hosseini H, Rajabi S, Shahidi S, Daraei A, Toofani Milani A. Expression and characterization of recombinant human epidermal growth factor receptor antigene (HER-2) as an indicator of breast cancer in yeast fermented systems. Koomesh 2016; 18: 110-116. (Persian).
• 10.
  Tai W, Mahato R, Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. J Control Release 2010; 146: 264-275.
• 11.
  Mohit E, Hashemi A, Allahyari M. Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines. Expert Rev Clin Immunol 2014; 10: 927-961.
• 12.
  Surez I, Salmern-Garca A, Cabeza J, Capitn-Vallvey LF, Navas N. Development and use of specific ELISA methods for quantifying the biological activity of bevacizumab, cetuximab and trastuzumab in stability studies. J Chromatogr B Analyt Technol Biomed Life Sci 2016; 1032: 155-164.
• 13.
  Cheng W, Allen T. The use of single chain Fv as targeting agents for immunoliposomes: an update on immunoliposomal drugs for cancer treatment. Expert Opin Drug Deliv 2010; 7: 461-478.
• 14.
  Damen CW, de Groot ER, Heij M, Boss DS, Schellens JH, Rosing H, et al. Development and validation of an enzyme-linked immunosorbent assay for the quantification of trastuzumab in human serum and plasma. Anal Biochem 2009; 391: 114-120.
• 15.
  Steinitz M. Quantitation of the blocking effect of tween 20 and bovine serum albumin in ELISA microwells. Anal Biochem 2000; 282: 232-238.
• 16.
  Sentandreu MA, Aubry L, Toldr F, Ouali A. Blocking agents for ELISA quantification of compounds coming from bovine muscle crude extracts. Eur Food Res Technol 2007; 224: 623-628.
• 17.
  Khan MS, Pande T, van de Ven TG. Qualitative and quantitative detection of T7 bacteriophages using paper based sandwich ELISA. Colloids Surf B Biointerfaces 2015; 132: 264-270.
• 18.
  Crowther R. The ELISA Guidebook. ed. Humana Press; 2009; 88-97.
• 19.
  Mosayebi G, Abtahi H, Ghazavi A, Zareinfar N, Khaki M, Payani MA. Design of enzyme-linked immunosorbent assay method for detection of anti-streptolysin-O antibodies on base of recombinant streptolysin-O. Koomesh 2012; 13: 362-368. (Persian).
• 20.
  Pterfi Z, Kocsis B. Comparison of blocking agents for an ELISA for LPS. J Immunoassay 2000; 21: 341-354.
• 21.
  Coory M, Thornton K. Randomised clinical endpoint studies for trastuzumab biosimilars: a systematic review. Breast Cancer Res Treat 2019; 1: 17-25.
• 22.
  Holbech H, Andersen L, Petersen GI, Korsgaard B, Pedersen KL, Bjerregaard P. Development of an ELISA for vitellogenin in whole body homogenate of zebrafish (Danio rerio). Comp Biochem Physiol C Toxicol Pharmacol 2001; 130: 119-131.
• 23.
  Dixit CK, Vashist SK, MacCraith BD, O'kennedy R. Multisubstrate-compatible ELISA procedures for rapid and high-sensitivity immunoassays. Nat Protoc 2011; 6: 439-445.
• 24.
  Kaur R, Dikshit KL, Raje M. Optimization of immunogold labeling TEM: an ELISA-based method for evaluation of blocking agents for quantitative detection of antigen. J Histochem Cytochem 2002; 50: 863-873.
• 25.
  Khodashenas S, Khalili S, Moghadam MF. A cell ELISA based method for exosome detection in diagnostic and therapeutic applications. Biotechnol Lett 2019; 41: 523-531.
• 26.
  Meysami P, Rezaei F, Marashi SM, Amiri MM, Bakker E, Mokhtari-Azad T. Antitumor effects of a recombinant baculovirus displaying anti-HER2 scFv expressing Apoptin in HER2 positive SK-BR-3 breast cancer cells. Future Virol 2019; 14: 139-152.
• 27.
  Maple L, Lathrop R, Bozich S, Harman W, Tacey R, Kelley M, Danilkovitch-Miagkova A. Development and validation of ELISA for Herceptin detection in human serum. J Immunol Methods 2004; 295: 169-182.
• 28.
  Tan WB, Jiang S, Zhang Y. Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference. Biomaterials 2007; 28: 1565-1571.
• 29.
  Alric C, Herv-Aubert K, Aubrey N, Melouk S, Lajoie L, Mme W, et al. Targeting HER2-breast tumors with scFv-decorated bimodal nanoprobes. J Nanobiotechnology 2018; 16: 18.
• 30.
  Lattrich C, Juhasz-Boess I, Ortmann O, Treeck O. Detection of an elevated HER2 expression in MCF-7 breast cancer cells overexpressing estrogen receptor 1. Oncol Rep 2008; 19: 811-817.
• 31.
  Huang R, Wang Q, Zhang X, Zhu J, Sun B. Trastuzumab-cisplatin conjugates for targeted delivery of cisplatin to HER2-overexpressing cancer cells. Biomed Pharmacother 2015; 72: 17-23.##https://doi.org/10.1016/j.biopha.2015.03.004.
• 32.
  Sarial S, Sonboli R, Maleknia S, Ashori F, Rezaeiravesh S, Nouri SZ, et al. Development, optimization and validation of a sandwich ELISA for detection of recombinant human factor VII. South Asian J Exper Biol 2015; 5: 26-31.##.